Significance of speckle-tracking in identifying subclinical myocardial injury of young patients with Type1 Diabetes mellitus without cardiovascular disease.
Reduction in hospitalisation for heart failure with empagliflozin is consistent across categories of baseline HbA1c and change in HbA1c: results from the EMPA-REG OUTCOME trial